Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma

  • Dolors Cuevas
  • Joan Valls
  • Sònia Gatius
  • Berta Roman-Canal
  • Elena Estaran
  • Eduard Dorca
  • Maria Santacana
  • Marta Vaquero
  • Núria Eritja
  • Ana Velasco
  • Xavier Matias-GuiuEmail author
Original Article


The two most frequent types of endometrial cancer (EC) are endometrioid (EEC) and serous carcinomas (SC). Differential diagnosis between them is not always easy. A subset of endometrial cancers shows misleading microscopical features, which cause problems in differential diagnosis, and may be a good scenario for next-generation sequencing. Previous studies have assessed the usefulness of targeted sequencing with panels of generic cancer-associated genes in EC histological typing. Based on the analysis of TCGA (The Cancer Genome Atlas), EEC and SC have different mutational profiles. In this proof of principle study, we have performed targeted sequencing analysis with a customized panel, based on the TCGA mutational profile of EEC and SC, in a series of 24 tumors (16 EEC and 8 SC). Our panel comprised coding and non-coding sequences of the following genes: ABCC9, ARID1A, ARID5B, ATR, BCOR, CCND1, CDH19, CHD4, COL11A1, CSDE1, CSMD3, CTCF, CTNNB1, EP300, ERBB2, FBXW7, FGFR2, FOXA2, KLLN, KMT2B, KRAS, MAP3K4, MKI67, NRAS, PGAP3, PIK3CA, PIK3R1, PPP2R1A, PRPF18, PTEN, RPL22, SCARNA11, SIN3A, SMARCA4, SPOP, TAF1, TP53, TSPYL2, USP36, and WRAP53. Targeted sequencing validation by Sanger sequencing and immunohistochemistry was performed in a group of genes. POLE mutation status was assessed by Sanger sequencing. The most mutated genes were PTEN (93.7%), ARID1A (68.7%), PIK3CA (50%), and KMT2B (43.7%) for EEC, and TP53 (87.5%), PIK3CA (50%), and PPP2R1A (25%) for SC. Our panel allowed correct classification of all tumors in the two categories (EEC, SC). Coexistence of mutations in PTEN, ARID1A, and KMT2B was diagnostic of EEC. On the other hand, absence of PTEN, ARID1A, and KMT2B mutations in the presence of TP53 mutation was diagnostic of SC. This proof of concept study demonstrates the suitability of targeted sequencing with a customized endometrial cancer gene panel as an additional tool for confirming histological typing.


Endometrial carcinoma Histological type Endometrioid Serous Biomarker Targeted sequencing 


Author’s contribution

Dolors Cuevas: collected samples, collected clinical patient data, performed experiments, analyzed data, participated in study design, and wrote, edited, and reviewed the manuscript.

Joan Valls: performed statistical analysis and wrote part of the manuscript.

Sònia Gatius: collected clinical and histological patient data, assisted in histopathological examinations, and wrote part of the manuscript.

Berta Roman-Canal: reviewed the manuscript.

Elena Estaran: assisted in histopathological examinations.

Eduard Dorca: assisted in histopathological examinations.

Maria Santacana: performed immunohistochemical experiments and wrote part of the manuscript.

Marta Vaquero: assisted in carrying out experiments and reviewed the manuscript.

Ana Velasco: participated in study design, assisted in carrying out experiments, and reviewed the manuscript.

Núria Eritja: assisted in data collection and reviewed the manuscript.

Xavier Matias-Guiu: conceived and designed the study and wrote, edited, and reviewed the manuscript.


The research team was supported by grants from the ISCIII (PI16/00692, CB16/12/00231) and Generalitat de Catalunya 2014SGR138. Tumor samples were obtained with the support of Xarxa Catalana de Bancs de Tumors and Plataforma de Biobancos ISCIII (PT 17/0015/0027).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

428_2018_2516_MOESM1_ESM.docx (64 kb)
ESM 1 (DOCX 64 kb)


  1. 1.
    Prat J (2004) Prognostic parameters of endometrial carcinoma. Hum Pathol 35:649–662CrossRefGoogle Scholar
  2. 2.
    Matias-Guiu X, Davidson B (2014) Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch 464:315–331CrossRefGoogle Scholar
  3. 3.
    Salvesen HB, Haldorsen IS, Trovik J (2012) Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 13:e353–e361CrossRefGoogle Scholar
  4. 4.
    Clarke BA, Gilks CB (2010) Endometrial carcinoma: controversies in histopathological assessment of grade and tumor cell type. J Clin Pathol 63:410–415CrossRefGoogle Scholar
  5. 5.
    Bartosch C, Manuel LJ, Oliva E (2011) Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv Anat Pathol 18:415–437CrossRefGoogle Scholar
  6. 6.
    Soslow RA (2013) High-grade endometrial carcinomas - strategies for typing. Histopathology 62:89–110CrossRefGoogle Scholar
  7. 7.
    Garg K, Soslow RA (2012) Strategies for distinguishing low-grade endometrioid and serous carcinomas of endometrium. Adv Anat Pathol 19:1–10CrossRefGoogle Scholar
  8. 8.
    Gilks CB, Oliva E, Soslow RA (2013) Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 37:874–881CrossRefGoogle Scholar
  9. 9.
    Cancer Genome Atlas Research Network (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73CrossRefGoogle Scholar
  10. 10.
    Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR, Gonzalez C, Ganesan R, Steele JC, Harrison BT, Oliva E, Vidal A, Matias-Guiu X, Abu-Rustum NR, Levine DA, Gilks CB, Soslow RA (2018) Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. Am J Surg Pathol 42:561–568Google Scholar
  11. 11.
    Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS, Chan JK (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94:642–646CrossRefGoogle Scholar
  12. 12.
    Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN (2015) A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 113:299–310CrossRefGoogle Scholar
  13. 13.
    Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT (2016) Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res 22:4215–4224CrossRefGoogle Scholar
  14. 14.
    Piulats JM, Guerra E, Gil-Martín M, Roman-Canal B, Gatius S, Sanz-Pamplona R, Velasco A, Vidal A, Matias-Guiu X (2017) Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol 145:200–207CrossRefGoogle Scholar
  15. 15.
    Moreno-Bueno G, Sanchez-Estevez C, Cassia R, Rodriguez-Perales S, Diaz-Uriarte R, Dominguez O, Hardisson D, Andujar M, Prat J, Matias-Guiu X, Cigudosa JC, Palacios J (2003) Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 63:5697–5702Google Scholar
  16. 16.
    Risinger JI, Maxwell GL, Chandramouli GV, Jazaeri A, Aprelikova O, Patterson T, Berchuck A, Barrett JC (2003) Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 63:6–11Google Scholar
  17. 17.
    Alvarez T, Miller E, Duska L, Oliva E (2012) Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Am J Surg Pathol 36:753–761CrossRefGoogle Scholar
  18. 18.
    Wik E, Raeder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M, Stefansson IM, Oyan AM, Kalland KH, Akslen LA, Salvesen HB (2013) Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res 19:1094–1105CrossRefGoogle Scholar
  19. 19.
    Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24:2376–2385CrossRefGoogle Scholar
  20. 20.
    Chen N, Yi X, Abushahin N, Pang S, Zhang D, Kong B, Zheng W (2010) Nrf2 expression in endometrial serous carcinomas and its precancers. Int J Clin Exp Pathol 4:85–96Google Scholar
  21. 21.
    Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB (2004) Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 23:129–137CrossRefGoogle Scholar
  22. 22.
    Yemelyanova A, Ji H, Shih I, Wang TL, Wu LS, Ronnett BM (2009) Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol 33:1504–1514CrossRefGoogle Scholar
  23. 23.
    McCluggage WG, Connolly LE, McBride HA, Kalloger S, Gilks CB (2012) HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. Histopathology 60:547–553CrossRefGoogle Scholar
  24. 24.
    Alkushi A, Clarke BA, Akbari M, Makretsov N, Lim P, Miller D, Magliocco A, Coldman A, van de Rijn M, Huntsman D (2007) Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 20:1156–1165CrossRefGoogle Scholar
  25. 25.
    Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA (2006) Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 19:1091–1100CrossRefGoogle Scholar
  26. 26.
    Santacana M, Maiques O, Valls J, Gatius S, Abó AI, López-García MÁ, Mota A, Reventós J, Moreno-Bueno G, Palacios J, Bartosch C, Dolcet X, Matias-Guiu X (2014) A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. Hum Pathol 45:2394–2403CrossRefGoogle Scholar
  27. 27.
    Yeramian A, Moreno-Bueno G, Dolcet X, Catasus L, Abal M, Colas E, Reventos J, Palacios J, Prat J, Matias-Guiu X (2013) Endometrial carcinoma: molecular alterations involved in tumors development and progression. Oncogene 32:403–413CrossRefGoogle Scholar
  28. 28.
    Llobet D, Pallares J, Yeramian A, Santacana M, Eritja N, Velasco A, Dolcet X, Matias-Guiu X (2009) Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol 62:777–785CrossRefGoogle Scholar
  29. 29.
    Chang YS, Huang HD, Yeh KT, Chang JG (2016) Genetic alterations in endometrial cancer by targeted next-generation sequencing. Exp Mol Pathol 100:8–12CrossRefGoogle Scholar
  30. 30.
    Krakstad C, Birkeland E, Seidel D, Kusonmano K, Petersen K, Mjøs S, Hoivik EA, Wik E, Halle MK, Øyan AM, Kalland KH, Werner HM, Trovik J, Salvesen H (2012) High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLoS One 7:e52795CrossRefGoogle Scholar
  31. 31.
    Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS (2018) Clinical targeted next-generation sequencing shows increased mutational load in endometrioid-type endometrial adenocarcinoma with deficient DNA mismatch repair. Int J Gynecol Pathol 37:581–589Google Scholar
  32. 32.
    McConechy MK, Ding J, Cheang MC, Wiegand KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T (2012) Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 228:20–30Google Scholar
  33. 33.
    Hoang LN, McConechy MK, Köbel M, Han G, Rouzbahman M, Davidson B, Irving J, Ali RH, Leung S, McAlpine JN, Oliva E, Nucci MR, Soslow RA, Huntsman DG, Gilks CB, Lee CH (2013) Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol 37:1421–1423CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Dolors Cuevas
    • 1
  • Joan Valls
    • 1
  • Sònia Gatius
    • 1
  • Berta Roman-Canal
    • 2
  • Elena Estaran
    • 1
  • Eduard Dorca
    • 2
  • Maria Santacana
    • 1
  • Marta Vaquero
    • 1
  • Núria Eritja
    • 1
  • Ana Velasco
    • 1
  • Xavier Matias-Guiu
    • 1
    • 2
    Email author
  1. 1.Hospital Universitari Arnau de Vilanova, Universitat de LleidaIRBLLEIDA, CIBERONCLleidaSpain
  2. 2.Hospital Universitari de BellvitgeIDIBELLBarcelonaSpain

Personalised recommendations